Cartesian Therapeutics (RNAC) Return on Sales (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Return on Sales data on file, last reported at 3.42% in Q1 2026.

• On a quarterly basis, Return on Sales fell 323.0% year-over-year to 3.42% in Q1 2026; TTM through Mar 2026 was 1.6%, a 157.0% decrease from a year earlier, with the FY2025 full-year figure at 0.47%, down 45.0% from the prior year.
• Return on Sales for Q1 2026 stood at 3.42%, down from 0.79% in the prior quarter.
• Over the last five years, Return on Sales for RNAC reached as high as 0.3% in Q4 2024 and fell as low as 4.27% in Q2 2025.
• Historically, Return on Sales has averaged 0.76% across 5 years, with a median of 0.03% in 2023.
• Across the five-year window, Return on Sales soared 54 bps in 2024 and sank 427 bps in 2025, its largest moves.
• Year by year, Return on Sales stood at 0.0% in 2022, then slumped by 6880 bps to 0.24% in 2023, then soared by 227 bps to 0.3% in 2024, then tumbled by 363 bps to 0.79% in 2025, then sank by 330 bps to 3.42% in 2026.
• Per Business Quant data, the three most recent Return on Sales figures were 3.42% in Q1 2026, 0.79% in Q4 2025, and 4.06% in Q3 2025.